Drug Profile
Research programme: targeted nanoparticle tolerance therapeutics - AnTolRx
Alternative Names: TNTTLatest Information Update: 22 Sep 2022
Price :
$50
*
At a glance
- Originator AnTolRx
- Developer AnTolRx; Pfizer
- Class Anti-inflammatories; Antigens; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Coeliac disease; Inflammatory bowel diseases; Multiple sclerosis; Myasthenia gravis; Psoriasis; Rheumatoid arthritis; Skin disorders; Type 1 diabetes mellitus
Most Recent Events
- 22 Sep 2022 Preclinical development is ongoing for Type-1 diabetes mellitus in USA (AnTolRx pipeline, September 2022)
- 21 Sep 2022 Preclinical trials in Autoimmune disorders in USA (unspecified route) (AnTolRx pipeline, September 2022)
- 21 Sep 2022 Preclinical trials in Coeliac disease in USA (unspecified route) prior to September 2022 (AnTolRx pipeline, September 2022)